ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysisA. Clamp, Jonathan A. Ledermann, Axel Walther et al.|International Journal of Gynecological Cancer|2026Cited by 1